IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about General Updates

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

IOLCP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.8%Reaction day

₹71.40

prior close

₹73.48

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%+4.6% vs market

Pharmaceuticals peers, median of 158sector-0.0%+4.8% vs sector

On the reaction day the stock moved 4.6 pts more than Nifty Microcap 250 and 4.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.8

10m

+0.4

15m

+0.6

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.8+0.2+4.6-0.0+4.8

Next day

+3.9+0.4+3.5+0.4+3.5

+2.9-0.6+3.6-0.5+3.5

+0.8-2.8+3.7-2.2+3.0

-0.8-5.4+4.6-3.2+2.4

-0.1-4.4+4.3-1.9+1.7

+0.7-7.1+7.8-4.3+5.0

15d

+2.1-7.8+9.9-5.5+7.6

+9.9-6.6+16.5-6.3+16.2

+29.4+7.7+21.7+3.0+26.3

+74.4+10.3+64.1+6.8+67.6

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 158Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

IOL Chemicals and Pharmaceuticals has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Health Care (EDQM) for its API product 'Clopidogrel Besilate' on 23rd February 2026. This is in addition to the existing CEP already held by the company for 'Clopidogrel Bisulphate.' Clopidogrel is an antiplatelet drug widely used for treating and preventing cardiovascular diseases. The CEP certification enables the company to supply this API to European pharmaceutical markets.

Likely market impact

This regulatory approval strengthens IOLCP's presence in the European API market and expands its cardiovascular product portfolio, which is positive for future export revenues. It signals compliance with stringent European quality standards, potentially boosting investor confidence.